Application of Harazon in the preparation of drugs for the prevention of parasitic nematodes
By using halazon as a nicotinamide enzyme inhibitor, the problems of high toxicity and drug resistance of existing inhibitors have been solved, providing an effective treatment for parasitic infections and achieving specific inhibition of nicotinamide enzyme.
Patent Information
- Application Number
- CN202611366415.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-04
- Publication Date
- 2026-11-17
AI Technical Summary
Existing nicotinamide enzyme inhibitors are highly toxic, irritating to cells, and prone to inducing drug resistance. There is a lack of highly effective and specific inhibitors, making it difficult to effectively inhibit the nicotinamide enzyme activity of parasitic nematodes.
Using halazon as a nicotinamide enzyme inhibitor, and combining it with other pharmaceutically acceptable excipients and carriers in liquid, solid, or semi-solid dosage forms, nicotinamide enzyme activity is inhibited, providing a novel therapeutic mechanism for parasitic infections.
Halazine can effectively inhibit nicotinamide enzyme activity with low toxicity, providing a novel treatment option against parasitic infections and is suitable for addressing drug resistance issues.
Smart Images

Figure CN123100622A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pesticide technology, specifically to the application of halazon in the preparation of drugs for the prevention of parasitic nematodes. Background Technology
[0002] Nicotinamide enzyme is NAD + This remedial enzyme, a key component of the NAD synthesis pathway, catalyzes the hydrolysis of nicotinamide to nicotinic acid, playing a crucial role in various microorganisms and parasites. Parasites themselves lack the complete de novo synthesis capability for NAD. + The parasite's ability to survive is highly dependent on this salvage pathway; therefore, the activity of nicotinamide directly affects the parasite's energy metabolism, cellular homeostasis, and survival ability, making it a potential target for antiparasitic drugs.
[0003] Multiple gene knockout experiments have demonstrated that inhibiting nicotinamide enzyme activity can effectively interfere with NAD in parasitic nematodes. + Metabolism shows significant antiparasitic effects; simultaneously, inhibiting nicotinamide enzymes prevents nicotinamide (NAM) from being converted into nicotinic acid (NA), and excessive NAM leads to the death of nematode germ cells and neurons; however, despite the promising prospects of this target, there is still a lack of highly efficient and specific nicotinamide enzyme inhibitors; among the currently known nicotinamide enzyme inhibitors, nicotinaldehyde is a typical broad-spectrum nicotinamide enzyme inhibitor, but because it belongs to the aldehyde class of compounds, it usually has strong irritant and cytotoxic properties, which can irritate the skin, eyes and respiratory mucosa, and can covalently react with biomolecules such as proteins and DNA, interfering with normal cell function and leading to cell damage or death; and the latest research shows that the metabolite TFNA-AM of the marketed insecticide FL, as a nicotinamide analog, can lead to the accumulation of nicotinamide. Insecticides like FL are known to cause insects (such as aphids and locusts) to exhibit symptoms similar to TRPV channel regulator poisoning, including abnormal behaviors such as insects stretching their legs or losing their balance.
[0004] Halazone (CAS: 80-13-7) is a disinfectant and preservative used for drinking water disinfection. At concentrations of 1 / 200,000 to 1 / 500,000, it can kill Escherichia coli, Salmonella typhi, Salmonella paratyphi, Cholera bacillus, and Shigella dysenteriae within 0.5 to 1 hour. According to research, halazone is less toxic than common nicotinic aldehyde analogs (nicotinic aldehyde, pyrazinaldehyde). However, current research has not found halazone to be used as a nicotinamide enzyme inhibitor. Summary of the Invention
[0005] To address or partially address the problems existing in related technologies, the primary objective of this invention is to provide an application of halazon in the preparation of drugs for the prevention of parasitic nematodes.
[0006] Preferably, the drug for preventing parasitic nematodes according to the present invention is one or more of the following: liquid dosage form, solid dosage form, or semi-solid dosage form.
[0007] Preferably, the antiparasitic nematode drug of the present invention comprises halazon and other pharmaceutically acceptable excipients and carriers.
[0008] The beneficial effects of this invention are:
[0009] (1) This invention is the first to discover that halazine can inhibit nicotinamide enzyme activity, and the inhibitory effect is proportional to the concentration of halazine.
[0010] (2) The halazon used in this invention can be used as a drinking water disinfectant and has low toxicity.
[0011] (3) The halazon used in this invention targets nicotinamide enzyme, a novel target, providing a new mechanism of action for the treatment of parasitic infections. In the context of the increasing severity of drug resistance in existing drugs, it has important translational value. Attached Figure Description
[0012] Figure 1 This is the purification result of nicotinamide enzyme Ce.PNC-1 in Example 1 of this invention; wherein Figure 1 (a) shows the purification results of nicotinamide enzyme Ce.PNC-1. Figure 1 (b) shows the elution curve of the gel filtration chromatography system. Figure 1 (c) SDS-PAGE analysis of elution buffer with elution volumes of 9-13 mL corresponding to the elution curve.
[0013] Figure 2 This is the purification result of nicotinamide enzyme Hc.PNC-1 in Example 1 of the present invention; wherein Figure 2 (a) shows the purification results of nicotinamide enzyme Hc.PNC-1. Figure 2 (b) shows the elution curve of the gel filtration chromatography system. Figure 2 (c) SDS-PAGE analysis of elution buffer with a volume of 10-13 mL corresponding to the elution curve.
[0014] Figure 3 This refers to the results of the nicotinamide enzyme Ce.PNC-1 activity assay in Example 2 of this invention, wherein... Figure 3 (a) shows the steady-state saturation curve of the initial rate of change in NAD(P)H absorbance with nicotinamide Ce.PNC-1 concentration. Figure 3 (b) is the steady-state saturation curve of the initial rate of change in the concentration of nicotinamide enzyme Hc.PNC-1 and the absorbance of NAD(P)H.
[0015] Figure 4 This is a comparison diagram of nicotinamide Ce.PNC-1 with nicotinamide enzymes of other species in Example 3 of the present invention.
[0016] Figure 5 This is a verification of the functional necessity of each residue in the nicotinamide enzyme Ce.PNC-1 catalytic triplet in Example 3 of the present invention; wherein Figure 5 (a) shows the three-dimensional structure of the metal ion binding site of the Ce.PNC-1 protein. Figure 5 (b) Enzyme activities of single-point mutants of D79A, K200A and C245A.
[0017] Figure 6 This is the structure of the complex of the substrate and nicotinamide enzyme Ce.PNC-1 in Example 3 of the present invention; wherein Figure 6 (a) is a schematic diagram of the structure of the K200A–NAM complex. Figure 6 (b) Key residues involved in NAM binding, shown in three-dimensional structure. Figure 6 (c) is LigPlot + The generated NAM binding two-dimensional interaction diagram, Figure 6 (d) shows a comparison of the structures of the protein K200A mutant and K200A+NAM.
[0018] Figure 7 This is the result of the interaction between harazon and nicotinamide in Example 4 of the present invention; wherein Figure 7 (a) shows the 3D interaction between harazonium and nicotinamide Ce.PNC-1. Figure 7 (b) shows the 2D interaction between harazonium and nicotinamide Ce.PNC-1. Figure 7 (c) shows the inhibitory effect of halazonium on nicotinamide enzyme Ce.PNC-1. Figure 7 (d) shows the inhibitory effect of halazon on nicotinamide enzyme Hc.PNC-1.
[0019] Figure 8 This refers to the inhibitory effect of 2-pyrazinaldehyde on nicotinamide enzyme in Example 4 of the present invention; wherein, Figure 8 (a) shows the inhibitory effect of 2-pyrazinaldehyde on nicotinamide enzyme Ce.PNC-1. Figure 8 (b) shows the inhibitory effect of 2-pyrazinaldehyde on nicotinamide enzyme Hc.PNC-1. Detailed Implementation
[0020] The present invention will be further described in detail below with reference to specific embodiments and accompanying drawings, but the scope of protection of the present invention is not limited to the content described therein; unless otherwise specified, all reagents used in the present invention are commercially available analytical grade reagents, and all raw materials used in the present invention can be purchased through conventional commercial channels.
[0021] The Caenorhabditis elegans used in this invention can be purchased through conventional procurement channels.
[0022] Example 1
[0023] The specific steps for purifying nicotinamide enzyme are as follows:
[0024] (1) RNA was extracted from Caenorhabditis elegans template using the phenol-chloroform extraction method, and the obtained RNA was reverse transcribed into Caenorhabditis elegans cDNA using the Hifair® AdvanceFast 1st Strand cDNA Synthesis Kit (Yisheng Biotechnology, 11149ES60).
[0025] (2) Using the Caenorhabditis elegans cDNA obtained in step (1) as a template, the nicotinamide enzyme coding sequence was amplified by PCR using specific primers. The forward primers for amplifying the nicotinamide enzyme coding sequence of Caenorhabditis elegans are shown in SEQ ID NO: 1, and the reverse primers are shown in SEQ ID NO: 2. The amplification system is shown in Table 1.
[0026] Table 1 PCR amplification system
[0027]
[0028] The PCR amplification procedure is shown in Table 2:
[0029] Table 2 PCR amplification program
[0030]
[0031] After PCR amplification, the PCR products were separated by 1% agarose gel electrophoresis, and the target band was recovered by a DNA gel recovery kit (Beijing Qingke Biotechnology Co., Ltd., TSP602-200) to obtain the nicotinamide enzyme coding sequence fragment of Caenorhabditis elegans, the amino acid sequence of which is shown in SEQ ID NO: 3.
[0032] (3) Construction of the recombinant expression vector for nicotinamide enzyme:
[0033] The pET28a vector and the nicotinamide enzyme coding sequence fragment were double-digested with restriction endonucleases NcoI and XhoI. The digestion system is shown in Table 3.
[0034] Table 3 Enzyme digestion system
[0035]
[0036] After the enzyme digestion system was thoroughly mixed, it was digested at 37℃ for 1 h. The digestion products were separated by 1% agarose gel electrophoresis, and the digestion products were then recovered by gel extraction using a DNA gel recovery kit to obtain the gel recovery product of the nicotinamide enzyme coding sequence fragment from *Caenorhabditis elegans* and the pET28a gel recovery product. The nicotinamide enzyme coding sequence fragment was ligated into the pET28a vector via T4 ligation to obtain the recombinant plasmid. The reaction system used for T4 ligation is shown in Table 4.
[0037] Table 4. T4 Connection Reaction System
[0038]
[0039] After mixing the T4 ligation reaction system, ligation was carried out at 25℃ for 1 h. The resulting product was transformed into Escherichia coli by heat shock and plated onto LB agar plates containing kanamycin (50 μg / mL). Screening was performed at 37℃, and after single colonies grew, single colonies were picked and transferred to LB liquid medium containing kanamycin (50 μg / mL). Amplification was carried out at 37℃ and 220 rpm for 12 h. Subsequently, according to the instructions of the high-purity plasmid DNA mini-extraction kit (Beijing Qingke Biotechnology Co., Ltd., TSP501-200), recombinant plasmids containing the nicotinamide enzyme gene of Caenorhabditis elegans were extracted.
[0040] The pET28a recombinant plasmid containing the nicotinamide gene of Haemonchus contortus was synthesized by Beijing Qingke Biotechnology Co., Ltd., and contains NcoI and XhoI restriction sites. The coding sequence fragment of nicotinamide from Haemonchus contortus is shown in SEQ ID NO: 4.
[0041] A recombinant plasmid containing the nicotinamide enzyme encoding sequence of *Caenorhabditis elegans* was transformed into strain BL21(DE3). The plasmid was plated onto LB agar plates containing kanamycin (50 μg / mL) and screened at 37°C. After single colonies emerged, each colony was transferred to 10 mL of LB liquid medium and cultured at 220 rpm in a 37°C shaker to obtain a seed culture. This seed culture was then inoculated into LB liquid medium at a rate of 1% of the LB liquid medium volume for expansion culture to obtain OD. 600 =0.6% bacterial solution - 1.
[0042] A recombinant plasmid containing the nicotinamide enzyme encoding sequence of *Haemonchus contortus* was transformed into strain BL21(DE3). The plasmid was plated onto LB agar plates containing kanamycin (50 μg / mL) and screened at 37°C. After single colonies emerged, each colony was transferred to 10 mL of LB liquid medium and cultured at 220 rpm in a 37°C shaker to obtain a seed culture. This seed culture was then inoculated into LB liquid medium at a rate of 1% of the LB liquid medium volume for expansion culture to obtain OD. 600 =0.6% bacterial solution - 2.
[0043] IPTG at a concentration of 0.5 mmol / L was added to bacterial culture-1 and bacterial culture-2 respectively, and the culture was placed in a constant temperature shaker at 16℃ and shaken at 180 rpm for 20 h to induce the expression of recombinant protein. After induction, bacterial culture-1 and bacterial culture-2 were collected by centrifugation. Bacterial culture-1 and bacterial culture-2 were disrupted 5 times by ultra-high pressure disruption (1000 bar), and supernatant-1 and supernatant-2 were collected by centrifugation respectively.
[0044] The Ni-NTA affinity chromatography packing material was equilibrated with 5 column volumes of Ni-NTA equilibration buffer (50 mmol / L Tris-HCl buffer, 200 mmol / L NaCl, pH=8.0). The supernatant-1 was mixed with the Ni-NTA affinity chromatography packing material and incubated for 2 h. The supernatant-1 / Ni-NTA affinity chromatography packing material mixture was then transferred to the chromatography column. After the supernatant-1 flow-through was complete, a portion of the flow-through was collected. The column was then washed with 20 mmol / L imidazole, and the eluent was collected. The eluent was then washed with imidazole at concentrations of 30, 50, and 200 mmol / L, respectively, and the 30 mmol / L, 50 mmol / L, and 200 mmol / L imidazole eluents were collected, respectively. The collected eluents were analyzed by SDS-PAGE. The results are shown below. Figure 1 As shown in (a), the nicotinamide enzyme Ce.PNC-1 content in the 200 mmol / L imidazole eluent was high, and its size was approximately 35-40 kDa.
[0045] 15 mL of the 200 mmol / L imidazole eluent from the supernatant-1 was transferred to an ultrafiltration centrifuge tube with a 10 kDa cutoff. The solution was concentrated to 500 μL at 4000 rpm in a centrifuge at 4 °C, yielding the concentrated 200 mmol / L imidazole eluent from the supernatant-1. This was then subjected to gel filtration chromatography using a Superdex 75 affinity column. The Superdex 75 column was equilibrated with equilibration buffer (20 mmol / L Tris-HCl buffer, 150 mmol / L NaCl, pH 8.0). The concentrated 200 mmol / L imidazole eluent from the supernatant-1 was then loaded onto the Superdex 75 affinity column at a flow rate of 0.4 mL / min. After loading the 200 mmol / L imidazole eluent from the supernatant-1, the column was further refluxed using a Superdex 75 column. Isocratic elution was performed on a 75 μm affinity chromatography column using equilibration buffer. 1 mL of eluent was collected per tube, for a total of 25 mL. The absorbance at 280 nm was recorded in real-time using a UV spectrophotometer connected to a gel filtration chromatography system. The results are as follows: Figure 1 As shown in (b), a distinct elution peak was observed at an elution volume of 11 mL during gel filtration chromatography. SDS-PAGE analysis was performed on the eluates obtained at elution volumes of 9, 10, 11, 12, and 13 mL, and the results are shown below. Figure 1 As shown in (c), the target protein Ce.PNC-1 was successfully separated from the impurities around 130 kDa, and the purified nicotinamide enzyme Ce.PNC-1 was obtained.
[0046] The Ni-NTA affinity chromatography packing material was equilibrated with 5 column volumes of Ni-NTA equilibration buffer (50 mmol / L Tris-HCl buffer, 200 mmol / L NaCl, pH 8.0). The supernatant-2 was mixed with the Ni-NTA affinity chromatography packing material and incubated for 2 h. The supernatant-2 / Ni-NTA affinity chromatography packing material mixture was then transferred to the chromatography column. After loading the supernatant-2, the column was washed with imidazole at concentrations of 30, 50, and 200 mmol / L, respectively. The 30 mmol / L, 50 mmol / L, and 200 mmol / L imidazole eluates were collected. The collected eluates were analyzed by SDS-PAGE. The results are shown below. Figure 2 As shown in (a), the content of nicotinamide enzyme Hc.PNC-1 in 200 mmol / L imidazole eluent is high, and its size is about 35-40 kDa.
[0047] 15 mL of the 200 mmol / L imidazole eluent from the supernatant-2 was transferred to an ultrafiltration centrifuge tube with a 10 kDa cutoff. The solution was concentrated to 500 μL at 4000 rpm in a centrifuge at 4 °C, yielding the concentrated 200 mmol / L imidazole eluent from the supernatant-2 (before sample loading). This was then subjected to gel filtration chromatography using a Superdex 75 affinity column. The Superdex 75 column was equilibrated with equilibration buffer (20 mmol / L Tris-HCl buffer, 150 mmol / L NaCl, pH 8.0). The concentrated 200 mmol / L imidazole eluent from the supernatant-2 was then loaded onto the Superdex 75 affinity column at a flow rate of 0.4 mL / min. After loading the 200 mmol / L imidazole eluent from the supernatant-2, the column was further refluxed using a Superdex 75 column. Isocratic elution was performed on a 75 μm affinity chromatography column using equilibration buffer. 1 mL of eluent was collected per tube, for a total of 25 mL. The absorbance at 280 nm was recorded in real-time using a UV spectrophotometer connected to a gel filtration chromatography system. The results are as follows: Figure 2 As shown in (b), a distinct elution peak was observed at an elution volume of 11.27 mL during gel filtration chromatography. SDS-PAGE analysis was performed on the concentrated supernatant (200 mmol / L imidazole eluent before sample loading) and the eluents at elution volumes of 10, 11, 12, and 13 mL. The results are shown in Figure 1. Figure 2 As shown in (c), the target protein and other proteins in the range of 70-100 kDa were successfully separated, and the purified nicotinamide enzyme Hc.PNC-1 was obtained.
[0048] Example 2
[0049] The specific steps for nicotinamide enzyme activity assay are as follows:
[0050] (1) Nicotinamide enzyme activity was determined using a glutamate dehydrogenase (GDH)-based coupling reaction system. The principle is that glutamate dehydrogenase (GDH) catalyzes the reaction of NH4⁺ with α-ketoglutarate and NAD(P)H, thereby detecting the change in absorbance of NAD(P)H. The 100µL reaction system contained 20mmol / L Tris-HCl buffer (pH=8.0, containing 150mmol / L NaCl), 1mmol / L α-ketoglutarate (CAS: 328-50-7), 500µmol / L reduced coenzyme II [NAD(P)H], 1.5U GDH, and 1mmol / L nicotinamide (CAS: The reaction mixture consisted of 98-92-0) and the purified nicotinamide enzyme Ce.PNC-1 from Example 1; wherein α-ketoglutarate was used as an amino acceptor, NAD(P)H was used as a reducing coenzyme and a fluorescent indicator, and GDH was used as a coupling enzyme. The reaction was initiated after the addition of nicotinamide enzyme. The initial rate of change of NAD(P)H absorbance in the reaction system was monitored in real time at a wavelength of 340 nm using a Synergy H1 multifunctional microplate reader at a concentration of 120 µmol / L.
[0051] The other 100 µL reaction system contained 20 mmol / L Tris-HCl buffer (pH=8.0, containing 150 mmol / L NaCl), 1 mmol / L α-ketoglutarate (CAS: 328-50-7), 500 µmol / L reduced coenzyme II [NAD(P)H], 1.5 U GDH, 1 mmol / L nicotinamide (CAS: 98-92-0), and the nicotinamide enzyme Hc.PNC-1 purified in Example 1. Using a Synergy H1 multi-functional microplate reader, the initial rate of change in NAD(P)H absorbance in the reaction system was monitored in real time at a wavelength of 340 nm at a concentration of 50 µmol / L.
[0052] (2) A steady-state saturation curve of nicotinamide enzyme Ce.PNC-1 on the substrate nicotinamide was constructed with the concentration of purified nicotinamide as the x-axis and the initial rate of change of NAD(P)H absorbance as the y-axis, as shown in the figure. Figure 3 As shown in (a), the Michaelis constant (Km) of nicotinamide enzyme Ce.PNC-1 is 169.1 µmol / L. A steady-state saturation curve of nicotinamide enzyme Hc.PNC-1 with respect to the substrate nicotinamide was constructed, with the concentration of purified nicotinamide enzyme Hc.PNC-1 as the x-axis and the initial rate of change in NAD(P)H absorbance as the y-axis, as shown in (a). Figure 3As shown in (b), the Michaelis constant (Km) of nicotinamide enzyme Hc.PNC-1 is 69.25 µmol / L, indicating that both nicotinamide enzyme Ce.PNC-1 and nicotinamide enzyme Hc.PNC-1 have an affinity for the substrate nicotinamide and can effectively catalyze the reaction under the corresponding substrate concentration conditions.
[0053] Example 3
[0054] The structural characterization of nicotinamide enzyme Ce.PNC-1 was performed using the following steps:
[0055] (1) The crystallization conditions of nicotinamide enzyme Ce.PNC-1 protein were screened using the sitting drop vapor diffusion method. The specific steps are as follows:
[0056] The purified nicotinamide Ce.PNC-1 from Example 1 was concentrated using a 10 kDa concentration tube to prepare a monodisperse nicotinamide Ce.PNC-1 protein solution with a concentration of 17.5 mg / mL. 100 μL of Hampton's crystallization buffer was then added to the groove of a dropper plate. Research, HR2-110, HR2-112, HR2-107, HR2-109, HR2-126, HR2-098, HR2-144), and added them to the sample wells of the droplet plate at a volume ratio of 1:1 with the precipitant solution to form initial crystal droplets; then the plate was sealed and placed in a 20°C constant temperature incubator for static incubation; the droplet state was monitored periodically by optical microscopy, and the crystal nucleation time, morphology and growth process were recorded, and the initial positive conditions were systematically optimized, including the ratio of nicotinamide enzyme Ce.PNC-1 protein solution / precipitant, pH, type of additive or temperature gradient, to obtain colorless and transparent crystals with clear boundaries and flat crystal faces for X-ray diffraction observed under an optical microscope; this process emphasizes the fine control of supersaturation kinetics to avoid disordered aggregation caused by rapid dehydration, thereby ensuring orderly crystal growth.
[0057] Finally, through system optimization, nicotinamide enzyme Ce.PNC-1 protein crystals meeting diffraction requirements were obtained with pH=5.5, PEG3350 at a concentration of 23% as a precipitant, and nicotinamide enzyme Ce.PNC-1 protein concentration of 17.5 mg / mL.
[0058] (2) The nicotinamide Ce.PNC-1 protein crystal was sent to the Shanghai Synchrotron Radiation Facility (SSRF) to collect X-ray diffraction data. The automated processing pipeline was used to automatically call XDS or DIALS to quickly generate the initial .mtz. The Ce.PNC-1 structure predicted by the AlphaFold3 server was used as the search model. The Phaser module in Phenix software was used to perform molecular substitution to obtain the initial phase information. Then, the model was manually built and adjusted in COOT and iteratively refined with the Refine module in Phenix to finally obtain the high-quality three-dimensional structure of Ce.PNC-1 wild type.
[0059] (2) The active site of Ce.PNC-1 protein was predicted using the PrankWeb server, identifying potential ligand-binding regions and key residues. Multiple sequence alignment (MSA) was used to analyze the homology of Ce.PNC-1 protein with Naam protein from Drosophila melanogaster, pnc1 protein from Leishmania infantum, pnc1 protein from Saccharomyces cerevisiae, and pncA protein from Escherichia coli. The results are as follows: Figure 4 As shown, the catalytic triplet (D79, K200, C245) is confirmed to be highly conserved in evolution. At the same time, a hydrophobic pocket rich in conserved hydrophobic residues was found near the catalytic triplet, suggesting its functional importance in substrate binding or conformational stability. Based on the above results, the region enclosed by the catalytic triplet (D79, K200, C245) and the metal ion binding residues (D124, H126, H175) is defined as the active pocket.
[0060] (3) To verify the functional necessity of each residue in the catalytic triplet, single-point mutants of D79A, K200A, and C245A were constructed. The three-dimensional structures of the metal ion binding sites of Ce.PNC-1 wild-type protein and the single-point mutants of D79A, K200A, and C245A are shown in the figure. Figure 5As shown in (a), the enzyme activities of D79A, K200A, and C245A single-point mutants were determined using a glutamate dehydrogenase (GDH)-based coupling reaction system. A 100 µL reaction system contained 20 mmol / L Tris-HCl buffer (pH=8.0, containing 150 mmol / L NaCl), 1 mmol / L α-ketoglutarate (CAS: 328-50-7), 500 µmol / L reduced coenzyme II [NAD(P)H], 1.5 U GDH, 1 mmol / L nicotinamide (CAS: 98-92-0), and the single-point mutant. Using a SynergyH1 multi-mode microplate reader at 340 nm, the initial rate of change in NAD(P)H absorbance in the reaction system was monitored in real time at a concentration of 120 µmol / L for the D79A, K200A, and C245A single-point mutants. The results are shown below. Figure 5 As shown in (b), the enzyme activity test results showed that all three mutants completely lost their catalytic activity, confirming that the catalytic triplet is indispensable for the catalytic function of Ce.PNC-1.
[0061] (4) To further elucidate the substrate recognition mechanism, the structure of the nicotinamide-protein complex needs to be determined. However, due to the fast catalytic rate of wild-type Ce.PNC-1, the residence time of nicotinamide at the active site is extremely short, making it difficult to capture the binding state of WT and substrate NAM through crystallization. Therefore, the K200A mutant, which has lost its catalytic activity, was used as a "substrate capture" tool. After the substrate enters the active site, it remains stably due to the inability to be catalyzed. K200A crystals were soaked in nicotinamide (NAM) at a concentration of 15 mmol / L for 15 min and sent to the Shanghai Synchrotron Radiation Facility (SSRF) to collect X-ray diffraction data. Using an automated processing pipeline, XDS or DIALS was automatically called to quickly generate the initial .mtz. The structure predicted by the AlphaFold3 server was used as the search model, and the Phaser module in Phenix software was used for molecular substitution to obtain the initial phase information. Subsequently, the model was manually built and adjusted in COOT, and iteratively refined with the Refine module in Phenix. Finally, the structure of the K200A-NAM complex was successfully obtained, as shown in the figure. Figure 6 As shown in (a); the key residues involved in NAM binding were also analyzed, and their three-dimensional structures are shown in Figure 1. Figure 6 As shown in (b); and using the NAM combined with the two-dimensional interaction plot generated by LigPlot+, as shown in... Figure 6 As shown in (c).
[0062] The structure of the K200A-NAM complex was compared with the apo state structure of K200A, and the results are as follows: Figure 6As shown in (d), NAM was found to bind to the hydrophobic pocket where the catalytic triplet is located, which perfectly matches the predicted location of the active pocket, verifying the accuracy of the previous prediction. Further structural comparison revealed that substrate binding induces significant conformational rearrangement of the two residues S208 and Y209, reducing the steric hindrance at the entrance of the active pocket and providing a structural basis for the entry of NAM, suggesting that Ce.PNC-1 recognizes the substrate through an induced fit mechanism.
[0063] Example 4
[0064] The specific steps for screening nicotinamide enzyme inhibitors are as follows:
[0065] (1) In the process of structure-based virtual screening and lead compound optimization, in order to improve screening efficiency and ensure that candidate molecules are drug-like, it is usually necessary to combine active reference compounds (positive control) and multi-dimensional physicochemical and energy parameters for hierarchical screening. In this invention, nicotinaldehyde (CAS: 500-22-1) is used as a positive control molecule, which is known to have a clear biological activity background and a molecular weight of about 107 Da, as a benchmark for evaluating ligand binding ability.
[0066] (2) The small molecules in the compound library established in our laboratory were docked with nicotinamide enzyme Ce.PNC-1. After the molecular docking calculation was completed, the candidate small molecules were initially screened based on the docking score. The screening threshold was set as docking score ≤ -4.0 kcal / mol (i.e. absolute value ≥ 4.0 kcal / mol). This standard aims to preferentially retain compounds with strong predicted binding affinity to the target protein. This threshold was based on the score obtained by the positive control nicotinic aldehyde under the same docking conditions. Molecules below this threshold may have weaker binding ability and lower priority, and can be eliminated. Based on the above principles, the candidate molecules for the first round of screening were selected.
[0067] (4) To further enhance the drug potential of candidate molecules, molecular weight is introduced as a key physicochemical parameter for the second round of screening. Compounds with smaller molecular weights usually have better membrane permeability, oral absorption potential and metabolic stability. Therefore, the further screening range is limited to compounds with molecular weight ≤300 Da. Compared with nicotinic aldehyde (MW=107 Da), this upper limit allows for moderate structural expansion to enhance activity, while avoiding reduced permeability due to excessively large molecules. Based on the above principles, virtual screening candidate molecules are selected.
[0068] (5) Enzyme activity assays were performed on candidate molecules that met the requirements after virtual screening, including nicotinyl-GABA (CAS: 34562-97-5), oxytetracycline (CAS: 5234-68-4), guanifacin hydrochloride (CAS: 29110-48-3), clonidine hydrochloride (CAS: 4205-91-8), clonidine (CAS: 4205-90-7), milrinone (CAS: 78415-72-2), isogratin (CAS: 57381-26-7), (R)-(-)-mandelic acid (CAS: 611-71-2), and gentianic acid. The enzyme activities of candidate molecules, including L-carnitine (CAS: 490-79-9), L-carnitine (CAS: 541-15-1), and halazine (CAS: 80-13-7), were determined at a final concentration of 50 µmol / L. The change in NAD(P)H absorbance at 340 nm was detected to determine whether the compound had an inhibitory effect. If the rate of decrease of NAD(P)H at 340 nm was significantly slowed down, it indicated that the compound had a certain inhibitory effect. Halazine (CAS: 80-13-7) was selected as the candidate molecule with an inhibitory effect, with a docking score of -4.3 and a molecular weight of 270.09 Da.
[0069] (6) Based on the molecular docking results in the above virtual screening, the interaction between harazonium and nicotinamide enzyme Ce.PNC-1 was analyzed, and their 3D interaction is as follows: Figure 7 As shown in (a), 2D interaction is as follows Figure 7 As shown in (b).
[0070] (7) Further verification of the inhibitory effect of halazine on nicotinamide enzyme Ce.PNC-1 by concentration gradient dependence was conducted. The inhibitory effects of halazine at concentrations of 50, 100, 200, 500 and 1000 µmol / L on Ce.PNC-1 in the enzyme activity assay system were measured, and the results are as follows: Figure 7 As shown in (c), the inhibitory effect of harazine on Ce. PNC-1 was positively correlated with the concentration of harazine; further, the inhibitory effects of harazine at concentrations of 10, 20, 50, 100, 200, 500, and 1000 µmol / L on Hc. PNC-1 were investigated, and the results are as follows. Figure 7 As shown in (d), the inhibitory effect of halazine on Hc.PNC-1 is positively correlated with the concentration of halazine, indicating a concentration-dependent relationship.
[0071] Meanwhile, using the nicotinic aldehyde analog 2-pyrazinaldehyde (CAS: 5780-66-5) as a control, the inhibitory effects of 2-pyrazinaldehyde at concentrations of 10, 20, 50, 100, 200, 500, and 1000 µmol / L on Ce.PNC-1 and Hc.PNC-1 were measured in the enzyme activity assay system. A blank control (0 µmol / L) without the addition of 2-pyrazinaldehyde was used. The results are as follows: Figure 8 As shown, 2-pyrazinaldehyde exhibits a strong inhibitory effect on Ce.PNC-1 and Hc.PNC-1, and is comparable to... Figure 7 In comparison, halazonium did not exhibit the same potent inhibitory effect on Ce.PNC-1 and Hc.PNC-1 as typical 2-pyrazine formaldehyde, but it still showed an inhibitory effect, and the effect was concentration-dependent.
[0072] Inhibition of nicotinamide enzymes at the metabolic level triggers two overlapping consequences: first, NAM cannot be converted into NA, leading to abnormal intracellular NAM accumulation; second, the interruption of NA supply hinders the substrate source of the Preiss-Handler pathway, resulting in a sharp decline in NAD⁺ regeneration flux; NAD + Exhaustion can trigger multiple parallel cellular dysfunction pathways, while excessive NAM can lead to the death of nematode germ cells and neurons, manifesting in reduced egg production and thus controlling the nematode population.
[0073] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.
Claims
1. The application of a harazon in the preparation of a drug for the prevention of parasitic nematodes.
2. The application according to claim 1, characterized in that, The drug for preventing parasitic nematodes is one or more of the following formulations: liquid, solid, or semi-solid.
3. The application according to claim 1, characterized in that, The drug for preventing parasitic nematodes contains halazon and other pharmaceutically acceptable excipients and carriers.
